admiral It posted a normalized net profit of 33.5 million euros in 2022, a figure 55.8% lower than in 2021, as reported by the biopharmaceutical company on Monday.
Total group revenue increased by 5% last year €878.5 millioncore net sales (excluding AstraZeneca and Covis) rose 6.6% to €863.2 million, driven by the European dermatology business.
Gross operating profit (ebitda), totaling €198.3 million in 2022, down 15.8% from 2021, which the company attributes to more investment in R&D and an increase in general and administrative expenses.
Second, it increased 4.3% to €409.7 million in 2022, thanks to support for final product launches. Wynzora and Klisyri Deployment of Ilumetri in Europe and new countries.
As a result, Almirall underlined that it managed to achieve its growth target in 2022 both in ‘core’ net sales and EBITDA. Achieving EBITDA by 2023 was set as the target. Between 165 and 180 million eurosand an increase in “basic” sales to “low to mid single digits”.
Almirall underlined that it has consolidated its position in Europe in 2022. 18.4% growth The dermatology business driven by new launches The company hopes the upcoming ‘lebrikizumab’ launch for atopic dermatitis will put it in a good position to accelerate its growth over the medium term.
“We are pleased that Almirall has achieved solid financial results in 2022 that meet our financial projections, thanks to the excellent performance of our core business, dermatology, which continues to deliver good results. Driven by the products we launched recently and the strength that our business in Europe demonstrates”, underlined Carlos Gallardo, president and CEO of Almirall.
Gallardo expects the company to maintain its positive trajectory throughout this year as it prepares for the launch of the company’s growth engines’ in 2023.lebrikizumab‘ for atopic dermatitis.
“We are in a very good position for growth in the medium and long term.. “The soundness of our balance sheet and the flexibility of our capital structure will enable us to continue to explore inorganic growth options aligned with our corporate strategy.”
Gallardo will continue as CEO
Certainly, the Almirall board asked Carlos Gallardo to continue as CEO and has suspended the search for a new CEO for the time being.”Following the company’s positive development, performance and momentum towards its key priorities in recent months“.
Gallardo, who accepted the council’s request, will continue his duty. Head of Administrative Advisor.
In addition, the council will create a new Management Committee controlling and balancing the position of the chairman-CEO as specified by the biopharmaceutical company.
The company also said it would offer a payment. 0.19 euro dividend per share, to be approved at the next annual general meeting scheduled for May 5, in an amount appropriate to the dividend amount of previous years.